Stem Cell-Derived Hepatocytes Could Replace Liver Transplants

Liver failure and inherited liver diseases affect millions worldwide, yet the supply of donor organs for transplantation falls far short of demand. Hepatocyte-based cell therapies — infusing functional liver cells directly into patients — have been explored for decades as a less invasive, scalable alternative. Despite genuine promise, clinical success has remained elusive, primarily because of two bottlenecks: sourcing sufficient numbers of high-quality hepatocytes and getting transplanted cells to engraft and persist in the host liver.

This review, published in Cell Stem Cell, takes a translational lens to the entire hepatocyte therapy landscape. The authors from the Shanghai Institute of Biochemistry and Cell Biology systematically analyze emerging cell sources, with particular emphasis on stem cell-derived hepatocytes — including induced pluripotent stem cell (iPSC)-derived and liver organoid-based approaches — evaluating each for therapeutic potential and readiness for clinical use.

The review organizes clinical applications into two paradigms. The first is long-term hepatocyte replacement, aimed at correcting inherited metabolic liver diseases or chronic liver failure by permanently integrating new functional cells. The second is temporary hepatocyte support, relevant in acute liver failure where bridging the patient until spontaneous recovery or transplant is the goal. Both paradigms face distinct manufacturing, engraftment, and immunological challenges.

Beyond hepatocytes, the authors extend their analysis to other liver cell types — including cholangiocytes and liver sinusoidal endothelial cells — highlighting preclinical advances that may broaden the therapeutic toolkit. They also discuss how hepatocyte therapies can complement emerging gene and RNA therapies, as well as xenotransplantation strategies, to create a more comprehensive treatment ecosystem for liver disease.

The review concludes by identifying critical unresolved gaps: GMP-compliant scalable manufacturing, optimized preconditioning regimens to prepare the liver for engraftment, long-term immune compatibility, non-invasive graft monitoring, and patient stratification to identify who will benefit most. Addressing these will be essential for moving hepatocyte therapies from promising science to routine clinical care.